Results 21 to 30 of about 16,419,568 (354)
The Korean Journal of Gastroenterology, 2021 Background/Aims: The HBsAg levels have been used to monitor the chronic hepatitis B (CHB) treatment response to antiviral therapy. On the other hand, it is unclear if the HBsAg quantification levels at each treatment point differ according to the HBeAg ...
Jong Hwa Na +4 more
doaj +1 more source
Virology Journal, 2019 Background Hepatitis B e antigen (HBeAg) seroconversion represents an endpoint of treatment of chronic hepatitis B virus (HBV) infections. Methods We have studied whether levels of serum hepatitis B virus ribonucleic acid (HBV RNA) during pegylated ...
Wen Jia +8 more
doaj +1 more source
International Journal of Preventive Medicine, 2018 Background: Scientists perceive drug users (DUs) as a high-risk population for hepatitis B virus (HBV) infection. Effective strategies aiming at the reduction of HBV infection can be depicted when its epidemiological status is clearly defined.
Roya Taleban +7 more
doaj +1 more source
Hepatitis B e antigen-negative chronic hepatitis B [PDF]
Hepatology, 2001 Summary HBeAg-negative CHB has now a worldwide distribution, developing in the course of HBeAg-positive chronic HBV infection during or after the phase of HBeAg loss and its seroconversion to anti-HBe. It is caused by replicating noncytopathic HBV mutants either unable to produce HBeAg (precore mutants) or with down-regulated transcription of the ...
Hadziyannis, SJ, Vassilopoulos, D
openaire +3 more sources
Revista Brasileira de Hematologia e Hemoterapia, 2012 OBJECTIVE: To evaluate viral vaccine antibody levels in children with acute lymphoblastic leukemia after chemotherapy and after vaccine booster doses.
Simone Santana Viana +5 more
doaj +1 more source
Monoclonal Antibodies Specific for Hepatitis B e Antigen and Hepatitis B Core Antigen
Hybridoma, 2011 Despite effective vaccination programs in many countries, HBV infection is still a serious health problem throughout the world; more than 2 billion people have been infected with Hepatitis B virus (HBV). The serologic markers are crucial indicators in clinical diagnosis of HBV infection. The persistent presence of anti-HBc is associated with chronicity,
Sogut, Ibrahim +3 more
openaire +4 more sources
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B [PDF]
Clinical Microbiology and Infection, 2014 Changes in two novel HBV serological markers, linearized hepatitis B surface antigen (HQ-HBsAg) and hepatitis B core-related antigen (HBcrAg), in the natural history of chronic hepatitis B (CHB) have not been well characterized. Serum HQ-HBsAg and HBcrAg levels of 404 Asian treatment-naïve CHB patients were analysed in a cross-sectional manner ...
Wong, DKH +6 more
openaire +4 more sources
Neutralization of the PTX3/CD44 axis suppresses TGF‐β1 signaling in kidney fibrosis
FEBS Letters, EarlyView.This study investigates how the PTX3/CD44 axis promotes kidney fibrosis by activating TGF‐β1 signaling. We demonstrate that the neutralizing antibody WHC‐001 effectively inhibits this pathway, suppressing myofibroblast activation and partial epithelial–mesenchymal transition (EMT).
Chao‐Chun Cheng +8 more
wiley +1 more source
PLoS ONE, 2020 The hepatitis B virus (HBV) envelope is composed of a lipid bilayer and three glycoproteins, referred to as the large (L), middle (M), and small (S) hepatitis B virus surface antigens (HBsAg). S protein constitutes the major portion of the viral envelope
Gi Uk Jeong +8 more
doaj +1 more source